XFOR:NASDAQX4 Pharmaceuticals, Inc. Analysis
Data as of 2026-09-24 - not real-time
$3.03
Latest Price
9/10Risk
Risk Level: High
Executive Summary
At $3.02, X4 Pharmaceuticals, Inc. shows a bearish moving-average alignment, with shorter averages beneath longer ones. Across the trailing 30 sessions it lost 29.3%. Momentum indicators put RSI at 26.9 (oversold) with MACD reading bearish. Price has been bracketed by support at $3.01 and resistance at $4.39.
The shares look undervalued, trading on 2.1 times earnings below a sector average of 30.6. Consensus targets land 283.5% above where the shares trade now. Revenue is growing at 346.3%.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 61.8%, a beta of 1.69 and a maximum drawdown of 35.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 2 out of 10.
The shares look undervalued, trading on 2.1 times earnings below a sector average of 30.6. Consensus targets land 283.5% above where the shares trade now. Revenue is growing at 346.3%.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 61.8%, a beta of 1.69 and a maximum drawdown of 35.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 2 out of 10.
Top Market Events
X4 Pharmaceuticals XFOR delivered earnings and revenue surprises of +31.X4 Pharmaceuticals XFOR might move higher on growing optimism about its earnings prospects, which is reflected by its...X4 Pharmaceuticals XFOR came out with a quarterly loss of $0.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked below long-term ones
- RSI at 26.9 signals oversold conditions
- Trading below the 200-day average of 3.93
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked below long-term ones
- RSI at 26.9 signals oversold conditions
- P/E of 2.1 versus sector average of 30.6
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- P/E of 2.1 versus sector average of 30.6
- Analyst targets imply +283.5% versus the current price
- Negative return on equity of -113.1%
Key Metrics & Analysis
Financial Health
Revenue Growth346.30%
P/E Ratio2.1
ROE-113.08%
ROA-28.15%
Debt/Equity49.68
P/B Ratio1.9
Op. Cash Flow$-83736000
Free Cash Flow$-53310876
Industry P/E30.6
Technical Analysis
TrendBearish
RSI26.9
Support$3.01
Resistance$4.39
MA 20$3.71
MA 50$3.92
MA 200$3.93
MACDBearish
VolumeIncreasing
Fear & Greed Index93.38
Valuation
Target Price$11.60
Upside/Downside283.47%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.69
Volatility61.80%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.